Roche Holding AG
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Effect of Hepatic Impairment on the Pharmacokinetics of Alectinib
- First Posted Date
- 2015-12-03
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT02621047
- Locations
- 🇸🇰
Summit Clinical Research s.r.o.; Oddelenie internej mediciny a klinickej farmakologie, Bratislava, Slovakia
🇨🇿Pharmaceutical Research Associates CZ, s.r.o., Praha 7, Czechia
A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)
- First Posted Date
- 2015-12-01
- Last Posted Date
- 2016-02-15
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 24
- Registration Number
- NCT02617784
A Study To Observe Treatment Patterns and Outcomes in Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer
- Conditions
- Breast Cancer, HER2 Positive Breast Cancer, Metastatic Breast Cancer, Locally Advanced Breast Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- Hoffmann-La Roche
- Registration Number
- NCT02616224
A Study of the Efficacy and Safety of Tocilizumab for Confirmed Rheumatoid Arthritis (RA) Participants in Clinical Practice
- Conditions
- Rheumatoid Arthritis
- Interventions
- Other: No intervention
- First Posted Date
- 2015-11-26
- Last Posted Date
- 2018-10-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 8
- Registration Number
- NCT02616328
- Locations
- 🇸🇦
King Khaled Uni Hospital; Oncology, Riyadh, Saudi Arabia
🇸🇦King Fahad Medical City; Gastroentrology, Riyadh, Saudi Arabia
A Study to Develop Predictive and Prognostic Tools for Optimizing Therapy With Bevacizumab Frontline Cancer Therapy in Participants With HER 2-Negative Aggressive Metastatic Breast Cancer
- First Posted Date
- 2015-11-24
- Last Posted Date
- 2020-02-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 111
- Registration Number
- NCT02613208
- Locations
- 🇪🇸
Hospital Provincial de Castellon; Servicio de Oncologia, Castellon de La Plana, Castellon, Spain
🇪🇸Hospital Universitario Son Espases; Servicio de Oncologia, Palma De Mallorca, Islas Baleares, Spain
🇪🇸Complejo Hospitalario Universitario A Coruña (CHUAC); Servicio de Oncologia, La Coruna, LA Coruña, Spain
Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Other: Observational Chemotherapy
- First Posted Date
- 2015-11-23
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 765
- Registration Number
- NCT02612077
Accu-Chek® CONNECT at School (CATS) Pediatric Study
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Device: DMSDevice: Accu-Chek® CONNECT DMS
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2018-05-18
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 196
- Registration Number
- NCT02609633
- Locations
- 🇺🇸
Pediatric Endocrinology of Phoenix, Phoenix, Arizona, United States
🇺🇸Barbara Davis Center for Childhood Diabetes, Aurora, Colorado, United States
🇺🇸Nemours Childrens Hospital, Pensacola, Florida, United States
A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
- Conditions
- Non-Hodgkin's Lymphoma
- Interventions
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 133
- Registration Number
- NCT02611323
- Locations
- 🇮🇹
Istituto Scientifico Romagnolo Per Lo Studio e La Cura Dei Tumori, Meldola, Emilia-Romagna, Italy
🇮🇹Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Lombardia, Italy
🇮🇹SCDU Ematologia, Novara, Piemonte, Italy
A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)
- Conditions
- Metastatic Breast Cancer
- Interventions
- Other: No intervention
- First Posted Date
- 2015-11-20
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 15
- Registration Number
- NCT02611310
- Locations
- 🇸🇦
National Guard King Abdulaziz Medical City; Oncology, Riyadh, Saudi Arabia
🇸🇦King Abdullah Medical City-Holy Makkah, Holy Makkah, Saudi Arabia
🇸🇦King Fahad Medical City; Gastroentrology, Riyadh, Saudi Arabia
A Study of Capecitabine (Xeloda) as First-Line Chemotherapy in Participants With Metastatic Nasopharyngeal Cancer
- First Posted Date
- 2015-11-18
- Last Posted Date
- 2016-03-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 45
- Registration Number
- NCT02608073